Reimbursement rates for Trastuzumab

As an antibody, Trastuzumab (Trastuzumab) has several properties, or is related to its Fab and/or Fc function, and a large number of patients with HER2-overexpressing breast cancer will initially or eventually become resistant to trastuzumab anti-HER2 therapy. The original trastuzumab drug is on the market in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications of this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may also be different. The information from the local medical insurance bureau may be more complete.